Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel. (PubMed, Cancer Treat Rev) - Sep 27, 2026 - "Available data suggest [177Lu]Lu-PSMA-617 as the preferred therapeutic option for the majority of patients with PSMA-positive mCRPC who progressed to ARPI and docetaxel. PSMA-RLT is preferred for most PSMA positive patients, with eligibility assessed individually rather than by rigid thresholds. Cabazitaxel remains a crucial treatment for patients with low PSMA expression, those ineligible for PSMA-RLT, or as an effective sequential therapy. Modern management of mCRPC demands a personalized, multidisciplinary approach to optimally balance survival gain with quality of life."
Clinical • Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1
|
|
Erica Palesandro; Francesco Ceci; Francesco Mattana; Giuseppe Curigliano; Marcello Tucci; Valentino Dragonetti
|